Compare Stocks: PCSC, EBS, ABEO, and RCKT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$7.16 -1.1%	$6.19	$4.00 ▼ $7.54	$408.33M	1.35	1.20 million shs	343,864 shs
EBS Emergent Biosolutions	$4.48 -7.4%	$7.82	$4.36 ▼ $14.06	$231.92M	2.35	892,390 shs	1.88 million shs
PCSC Perceptive Capital Solutions	$11.95	$11.41	$9.95 ▼ $14.47	$97.48M	0.36	238,297 shs	N/A
RCKT Rocket Pharmaceuticals	$3.62 +0.1%	$3.33	$2.53 ▼ $5.45	$394.72M	0.47	2.75 million shs	698,968 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	0.00%	+12.77%	+3.72%	+23.55%	+15.65%
EBS Emergent Biosolutions	0.00%	-32.73%	-39.53%	-46.02%	-43.31%
PCSC Perceptive Capital Solutions	0.00%	0.00%	+10.65%	+5.94%	-9.23%
RCKT Rocket Pharmaceuticals	0.00%	+16.08%	-7.67%	+0.56%	+26.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$7.16 -1.1%	$6.19	$4.00 ▼ $7.54	$408.33M	1.35	1.20 million shs	343,864 shs
EBS Emergent Biosolutions	$4.48 -7.4%	$7.82	$4.36 ▼ $14.06	$231.92M	2.35	892,390 shs	1.88 million shs
PCSC Perceptive Capital Solutions	$11.95	$11.41	$9.95 ▼ $14.47	$97.48M	0.36	238,297 shs	N/A
RCKT Rocket Pharmaceuticals	$3.62 +0.1%	$3.33	$2.53 ▼ $5.45	$394.72M	0.47	2.75 million shs	698,968 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	0.00%	+12.77%	+3.72%	+23.55%	+15.65%
EBS Emergent Biosolutions	0.00%	-32.73%	-39.53%	-46.02%	-43.31%
PCSC Perceptive Capital Solutions	0.00%	0.00%	+10.65%	+5.94%	-9.23%
RCKT Rocket Pharmaceuticals	0.00%	+16.08%	-7.67%	+0.56%	+26.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	2.33	Hold	$19.00	165.36% Upside
EBS Emergent Biosolutions	2.40	Hold	$10.00	123.02% Upside
PCSC Perceptive Capital Solutions	1.00	Sell	N/A	N/A
RCKT Rocket Pharmaceuticals	2.30	Hold	$8.71	141.06% Upside

Current Analyst Ratings Breakdown

Latest PCSC, EBS, ABEO, and RCKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$12.00 ➝ $10.00
8/7/2026	EBS Emergent Biosolutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/3/2026	ABEO Abeona Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
7/20/2026	PCSC Perceptive Capital Solutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/15/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/29/2026	ABEO Abeona Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
6/29/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	PCSC Perceptive Capital Solutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
6/2/2026	EBS Emergent Biosolutions	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/2/2026	EBS Emergent Biosolutions	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/1/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$5.82M	70.11	N/A	N/A	$2.94 per share	2.44
EBS Emergent Biosolutions	$742.30M	0.31	$3.40 per share	1.32	$9.95 per share	0.45
PCSC Perceptive Capital Solutions	N/A	N/A	$0.09 per share	127.23	($0.77) per share	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$2.56 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	$71.18M	$0.97	7.39	N/A	N/A	N/A	-53.98%	-38.52%	8/13/2026 (Estimated)
EBS Emergent Biosolutions	$52.60M	-$3.55	N/A	N/A	N/A	-22.95%	16.35%	6.17%	10/28/2026 (Estimated)
PCSC Perceptive Capital Solutions	$840K	-$0.06	N/A	N/A	N/A	N/A	-2.70%	-0.84%	N/A
RCKT Rocket Pharmaceuticals	-$223.12M	-$1.87	N/A	N/A	N/A	N/A	-69.61%	-58.63%	N/A

Latest PCSC, EBS, ABEO, and RCKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ABEO Abeona Therapeutics	-$0.23	N/A	N/A	N/A	$12.24 million	N/A
8/5/2026	Q2 2026	EBS Emergent Biosolutions	-$0.0850	$0.60	+$0.6850	-$3.49	$177.50 million	$234.30 million
7/15/2026	Q2 2026	PCSC Perceptive Capital Solutions	N/A	-$0.01	N/A	-$0.01	N/A	N/A
5/13/2026	Q1 2026	ABEO Abeona Therapeutics	-$0.33	-$0.30	+$0.03	-$0.30	$4.57 million	$8.72 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
PCSC Perceptive Capital Solutions	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.03	5.89	5.70
EBS Emergent Biosolutions	1.70	5.42	2.95
PCSC Perceptive Capital Solutions	N/A	0.20	0.20
RCKT Rocket Pharmaceuticals	0.08	6.12	6.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
EBS Emergent Biosolutions	78.40%
PCSC Perceptive Capital Solutions	N/A
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	7.10%
EBS Emergent Biosolutions	6.00%
PCSC Perceptive Capital Solutions	22.06%
RCKT Rocket Pharmaceuticals	21.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	56.99 million	52.95 million	Optionable
EBS Emergent Biosolutions	2,420	51.60 million	48.20 million	Optionable
PCSC Perceptive Capital Solutions	N/A	8.16 million	6.36 million	N/A
RCKT Rocket Pharmaceuticals	240	109.19 million	85.94 million	Optionable

PCSC, EBS, ABEO, and RCKT Headlines

Recent News About These Companies

Rocket Pharmaceuticals (NASDAQ:RCKT) Lowered to "Sell" Rating by Wall Street Zen

August 9 at 2:14 AM | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Rating Lowered to Sell at Wall Street Zen

August 9 at 1:11 AM | marketbeat.com

Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial

August 3, 2026 | benzinga.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Upgraded by Wall Street Zen

August 1, 2026 | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Raised to Hold at Wall Street Zen

August 1, 2026 | marketbeat.com

Rocket Pharmaceuticals (RCKT) to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Rocket Pharmaceuticals: Can The AAV9 Cardiovascular Pipeline Justify The Current Valuation?

July 29, 2026 | seekingalpha.com

Maverick Capital Ltd. Purchases 1,054,262 Shares of Rocket Pharmaceuticals, Inc. $RCKT

July 28, 2026 | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of "Hold" from Analysts

July 27, 2026 | marketbeat.com

Wall Street Zen Downgrades Rocket Pharmaceuticals (NASDAQ:RCKT) to Sell

July 18, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Pass Below 200 Day Moving Average - What's Next?

July 14, 2026 | marketbeat.com

Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?

June 25, 2026 | insidermonkey.com

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

June 12, 2026 | rutlandherald.comR

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

June 12, 2026 | businesswire.com

Rocket Pharmaceuticals, Inc. (RCKT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 9, 2026 | seekingalpha.com

Rocket Pharmaceuticals, Inc. (RCKT) Presents at Jefferies Global Healthcare Conference 2026 Transcript

June 5, 2026 | seekingalpha.com

Rocket Pharmaceuticals (NASDAQ:RCKT) CEO Gaurav Shah Sells 55,684 Shares

May 27, 2026 | insidertrades.com

Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where’s the Stock Going?

May 20, 2026 | finance.yahoo.com

Rocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6M

May 18, 2026 | finance.yahoo.com

Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Sells 3,361 Shares of Stock

May 15, 2026 | insidertrades.com

Sarbani Chaudhuri Sells 17,650 Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

May 12, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSC, EBS, ABEO, and RCKT Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$7.16 -0.08 (-1.10%)

As of 12:28 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Emergent Biosolutions NYSE:EBS

$4.48 -0.36 (-7.36%)

As of 12:27 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Perceptive Capital Solutions NASDAQ:PCSC

$11.95 0.00 (0.00%)

As of 07/21/2026

Perceptive Capital Solutions Corp is a blank check company. It formed for the purpose of entering into a combination with one or more businesses or entities. Perceptive Capital Solutions Corp is based in NEW YORK.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.62 +0.01 (+0.14%)

As of 12:27 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PCSC, EBS, ABEO, and RCKT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PCSC, EBS, ABEO, and RCKT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PCSC, EBS, ABEO, and RCKT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSC, EBS, ABEO, and RCKT Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

Emergent Biosolutions NYSE:EBS

Perceptive Capital Solutions NASDAQ:PCSC

Rocket Pharmaceuticals NASDAQ:RCKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PCSC, EBS, ABEO, and RCKT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PCSC, EBS, ABEO, and RCKT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PCSC, EBS, ABEO, and RCKT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSC, EBS, ABEO, and RCKT Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

Emergent Biosolutions NYSE:EBS

Perceptive Capital Solutions NASDAQ:PCSC

Rocket Pharmaceuticals NASDAQ:RCKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools